Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06217302

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease (SUGARNSALT)

Effectiveness and Safety of Sotagliflozin in Slowing Kidney Function Decline in Persons With Type 1 Diabetes and Moderate to Severe Diabetic Kidney Disease

Sponsor: Alessandro Doria

Conditions Diabetes Mellitus Type 1 Diabetic Nephropathies Heart Failure Kidney Failure, Chronic

Interventions Placebo Sotagliflozin

Updated 11 times since 2024 Last updated: Sep 9, 2025 Started: Oct 31, 2024 Primary completion: Dec 31, 2028 Completion: May 31, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Diabetes Mellitus Type 1 and Diabetic Nephropathies and is currently actively recruiting participants. Alessandro Doria leads this study, which shows 11 recorded versions since 2024 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

11 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE3
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE3
Jun 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Apr 2025 — Jun 2025 [monthly]

Recruiting PHASE3
Jan 2025 — Apr 2025 [monthly]

Recruiting PHASE3

▶ Show 6 earlier versions

Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Nov 2024 — Dec 2024 [monthly]

Not Yet Recruiting PHASE3
Oct 2024 — Nov 2024 [monthly]

Not Yet Recruiting PHASE3
Sep 2024 — Oct 2024 [monthly]

Not Yet Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE3
Feb 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alessandro Doria
Breakthrough T1D
Canadian Institutes of Health Research (CIHR)
DexCom, Inc.
Institut de Recherches Cliniques de Montreal
Joslin Diabetes Center
LMC Diabetes & Endocrinology Ltd.
Lexicon Pharmaceuticals
Montefiore Medical Center
Northwestern University
Providence Medical Research Center
Stanford University
State University of New York - Upstate Medical University
The Cleveland Clinic
The Kidney Foundation of Canada
University Health Network, Toronto
University of Alberta
University of British Columbia
University of Calgary
University of Colorado, Denver
University of Michigan
University of Toronto
University of Washington
Washington University School of Medicine

Data source: Joslin Diabetes Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Boston, United States , Calgary, Canada , Chicago, United States , Cleveland, United States , Dallas, United States , Edmonton, Canada , Montreal, Canada , Portland, United States , Seattle, United States and 7 more locations